In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PIramed Ltd.

Executive Summary

PIramed Ltd. was incorporated in October 2001 to commercialize the findings of a research collaboration between three of Europe's leading cancer research institutes (the Ludwig Institute for Cancer Research, Cancer Research UK and the Institute for Cancer Research) and Yamanouchi Pharmaceutical Co. Ltd. The collaboration, initiated in 1995, identified a range of small molecule inhibitors of the PI3 Kinase (PI3K) family of lipid kinases-intracellular enzymes that are important in cell signalling pathways that influence a range of fundamental cellular activities including growth, migration, proliferation and survival, and are implicated in a number of diseases, including cancer, cardiovascular, neurodegenerative and immune-inflammatory diseases.

You may also be interested in...



Private Device Companies Step-Up to the Public Market

Encouraged by successes in the biotech space, public market investors' interest in the device arena has returned in 2004 to support 10 companies' IPOs so far. Windhover's analysis of the valuations achieved indicate that private investors in these companies have, on average, enjoyed larger returns than their biotech counterparts.

Senexis Ltd.

Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.

Lectus Therapeutics Ltd.

Lectus was founded in December 2002, to develop and commercialize a second generation of ion channel modulating drugs. By targeting the plethora of accessory proteins that regulate the activity of the ion channel pore-forming proteins rather than the pore-forming proteins themselves Lectus believes its drugs will be safer and more effective than currently marketed products.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL082593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel